Glioblastoma angiogenesis: VEGF resistance solutions and new strategies based on molecular mechanisms of tumor vessel formation

Brain Tumor Pathology

Volumn 29, Issue 2, 2012, Pages 73-86

  Takano, Shingo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cancer stem like cell transdifferentiation; Normal vessel formation; Resistance to VEGF blockade; Tumor vessel formation; Vasculogenic mimicry

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; AX 102; BEVACIZUMAB; CEDIRANIB; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; JAGGED1; MICRORNA; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR C; PLERIXAFOR; ROQUINIMEX; STROMAL CELL DERIVED FACTOR 1; TRABECTEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL TRANSDIFFERENTIATION; CYTOLOGY; DRUG RESEARCH; DRUG TARGETING; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; REVIEW; SOFT TISSUE SARCOMA; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862766496     PISSN: 14337398     EISSN: 1861387X     Source Type: Journal    
DOI: 10.1007/s10014-011-0077-6     Document Type: Review

References (100)

1. Jain RK, di Tomaso E, Duda DG et al (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 9:610-622 (Pubitemid 47093931)
2. Beal K, Abrey LE, Gutin PH (2011) Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 6:2. doi:10.1186/1748-717x-6-2
3. Norden AD, Drappatz J, Wen PY (2008) Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152-1160
4. Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69-82 (Pubitemid 46054518)
5. Ricci-Vitiani L, Pallini R, Biffoni M et al (2010) Tumour vascularization via endothelial differentiation of glioblastoma stemlike cells. Nature 468:824-828
6. Wang R, Chandalavada K, Wilshire J et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468: 829-833
7. Soda Y, Marumoto T, Friedmann-Morvinski D et al (2011) Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 18:4274-4280
8. Charles NA, Holland EC, Gilbertson R et al (2011) The brain tumor microenvironment. Glia 59:1169-1180
9. Bergers G, Hanahan D (2008) Modes of resistance to antiangiogenic therapy. Nature Rev Cancer 8:592-603
10. Ferrara N (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21:21-26
11. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalize tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95 (Pubitemid 46075199)
12. Lieu C, Heymach J, Overman M et al (2011) Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res 17:6130-6139
13. di Tomaso E, Snudel M, Kamoun WS et al (2011) Glioblastoma recurrence after cediranib therapy in patients: lack of rebound revascularization as mode of escape. Cancer Res 71:19-28
14. Ebos JML, Lee CR, Cruz-Hunoz W et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15:232-239
15. de Groot JF, Fuller G, Kumar AJ et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathological correlation in humans and mice. Neuro-Oncol 12:233-242
16. Kenig S, Alonso MBD, Mueller MM et al (2010) Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP9. Cancer Lett 289: 53-61
17. Lucio-Etervic AK, Piao Y, de Groot JF et al (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15:4589-4599
18. Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220-231
19. Mizukami Y, Li J, Zhang X et al (2004) Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res 64:1765-1772 (Pubitemid 38428700)
20. Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-306
21. Kioi M, Vogel H, Schultz G et al (2010) Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 120:694-705
22. Stockmann C, Doedens A, Weidermann A et al (2008) Deletion of vascular endothelial growth factor in myeloid cells accelerate tumorigenesis. Nature 456:814-818
23. Potente M, Gerhardt H, Carmeliet P (2011) Basic and therapeutic aspects of angiogenesis. Cell 146:873-887
24. Gabrusiewiczk K, Ellert-Miklaszewska A, Lipko M et al (2011) Characteristics of the alternative phenotype of microglia/ macrophages and its modulation in experimental gliomas. PLos One 6:e23902
25. Mukhtar RA, Nseyo O, Campbell MJ et al (2011) Tumorassociated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11: 91-100
26. Cimini E, Piacentini P, Sacchi A et al (2011) Zoledronic acid enhances V2 T-lymphocyte antitumor response to human glioma cell lines. Int J Immunopathol Pharmacol 24:139-148
27. Clavreul A, Etcheverry A, Chassevent A et al. (2011) Isolation of a new cell population in the glioblastoma microenvironment. J Neurooncol. doi:101007/s11060-011-0701-7
28. Grau S, Thorsteinsdottir J, von Baumgarten L et al (2011) Bevacizumab can induce reactivity to VEGF-C and -D in human brain and tumour derived endothelial cells. J Neurooncol 104: 103-112
29. Keunen O, Johansson M, Oudin A et al (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108: 3749-3754
30. Gaengeal K, Genove G, Armulik A et al (2009) Endothelialmural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29:630-638
31. Greenberg JI, Shields DJ, Barillas SG et al (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456:809-813
32. Bergers G, Sons S (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncol 7:452-464 (Pubitemid 41555617)
33. Ribatti D, Nico B, Crivellato E (2011) The role of pericytes in angiogenesis. Int J Dev Biol 55:261-268
34. Bergers G, Song S, Meyer-Morse N et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295 (Pubitemid 36554699)
35. Sennino B, Falcon BL, Mggauley D et al (2007) Sequential loss of tumor vessel pericytes and endothelial cells after inhibitor of platelet derived growth factor B by selective aptamer AX102. Cancer Res 67:6367-7358
36. Pietras K, Hanahan D (2005) A multi targeted, metronomic and maximum-tolerated dose ''chemo-switch'' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23:939-952 (Pubitemid 46202314)
37. Fong GH (2008) Mechanisms of adaptive angiogenesis to tissue hypoxia. Angiogenesis 11:121-140
38. Sjostrom SW, Wibom C, Andersson U et al (2011) Genetic variations in VEGF and VEGFR2 and glioblastoma outcome. J Neurooncol 104:523-527
39. Mazzone M, Dettori D, de Oliveira RL et al (2009) Heterozygous deficiency of PhD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839-851
40. Marumoto T, Tashiro A (2009) Friedmann-Morvinski D et al (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15:110-116
41. Inoue S, Ichikawa T, Kurozumi K et al (2011) Novel animal glioma models that separately exhibit two different invasive and angiogenic phenotypes of human glioblastoma. World Neurosurgery. doi:10.1016/j.wneu.2011.09005
42. Phng LK, Gerhardt H (2009) Angiogenesis: a team effort coordinated by NOTCH. Dev Cell 16:196-208
43. Benedit R, Roca C, Sorensen I et al (2009) The Notch ligands Dll4 and jagged1 have opposing effects on angiogenesis. Cell 137:1124-1135
44. Styp-Rekouska B, Hlushchuk R, Pries AR et al (2011) Intussusceptive angiogenesis: pillars against the blood flow in the rising capillary sprout. Acta Physiol (oxf) 202:213-223
45. Hlushchuk R, Riesterer O, Baum O et al (2008) Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 173:1173-1785
46. Holash J, Maisonpierre PC, Compton D et al (1999) Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284:1994-1998 (Pubitemid 29309448)
47. Zagzag D, Amirnovin R, Greco MA et al (2000) Vascular apoptosis and involution in glioma precede neovascularization: a novel concept for glioma and angiogenesis. Lab Invest 80: 837-849 (Pubitemid 30421801)
48. Brat DJ, van Meir EG (2004) Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest 84:397-405 (Pubitemid 41656467)
49. Arismerdi-Morillo G, Castellano A (2005) Tumoral micro-blood vessels and vascular microenvironment in the astrocytic tumors. A transmission electron microscopy study. J Neuro-oncol 73: 211-217 (Pubitemid 40974016)
50. Sharma S, Sharma MC, Gupta DK et al (2006) Angiogenic patterns and their quantitation in high grade astrocytomas. J Neurooncol 79:19-30 (Pubitemid 44057411)
51. Takeuchi H, Hashimoto N, Kitai R et al (2010) Proliferation of vascular smooth muscle cells in glioblastoma. J Neurosurg 113: 218-224
52. Komatsu H, Sugita Y, Arakawa F et al (2009) Expression of CXCL12 on pseudopalisading cells and proliferating microvessels in glioblastomas: an accelerated growth factor in glioblastomas. Int J Oncol 34:665-672
53. Arismendi-Morillo G (2011) Electron microscopy morphology of the mitochondrial network in glioma and their vascular component. Biochim Biophys Acta 1807:602-608
54. Dilera A, Grizzi F, Sherif C et al (2011) Angioarchitectural heterogeneity in human glioblastoma multiforme: a fractalbased histopathological assessment. Microvasc Res 81:222-230
55. Hida K, Hida Y, Amin DN et al (2004) Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 64: 8249-8255 (Pubitemid 39491762)
56. Akino T, Hida K, Hida Y et al (2009) Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am J Pathol 175:2657-2667
57. Storchova Z, Pellman D (2004) From polyploidy to aneuploidy, genome instability and cancer. Natl Rev Mol Cell Biol 5:45-54 (Pubitemid 38089840)
58. Bergsmedh A, Szeles A, Henriksson M et al (2001) Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 98:6407-6411 (Pubitemid 32488250)
59. Bussolati B, Grange C, Camussi G (2011) Tumor exploits alternative strategies to achieve vascularization. FASEB J 25: 2874-2882
60. Gunsllius E (2003) Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Adv Exp Med 522:17-24
61. Taylor SM, Nevis KR, Plate HL et al (2010) Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels. Blood 116:3108-3117
62. Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155:739-752 (Pubitemid 29426820)
63. Folberg R, Hendrix MJC, Maniotis AJ (2000) Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 156:361-381 (Pubitemid 30648785)
64. Dong J, Zhang Q, Huang Q et al (2010) Glioma stem cells involved in tumor tissue remodeling in a xenograft model. J Neurosurg 113:249-260
65. Sneubel B, Chott A, Huber D et al (2004) Lymphoma specific genetic abnormalities in microvascular endothelial cells i8n B cell lymphomas. N Engl J Med 351:250-259 (Pubitemid 38916042)
66. Pezzolo A, Parodi F, Corrias MV et al (2007) Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol 25: 376-383 (Pubitemid 350002985)
67. Rigolin GM, Fraulini C, Ciccone M et al (2006) Neoplastic circulating endothelial cells in multiple myeloma with 13q deletion. Blood 107:2531-2535 (Pubitemid 43345578)
68. Bussolati B, Grange C, Sapino A et al (2009) Endothelial cell differentiation of human breast tumor stem/progenitor cells. J Cell Mol Med 13:309-319
69. Su M, Feng YS, Yao LQ et al (2008) Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer 18:476-480
70. Hallani SE, Boisselier B, Peglion F et al (2010) A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133:973-982
71. Yue WY, Chen ZP (2005) Does vasculogenic mimicry exist in astrocytoma? J Histochem Cytochem 53:997-1002
72. Liu X, Zhang Q, Mu Y et al (2011) Clinical significance of vasculogenic mimicry in human gliomas. J Neurooncol. doi: 10.1007/s11060-011-0578-5
73. Yao XH, Ping YF, Blan XW (2011) Contribution of cancer stem cells to tumor vasculogenic mimicry. Protein Cell 2:266-272
74. Zhang S, Guo H, Zhang D et al (2006) Microcirculation patterns in different stages of melanoma growth. Oncol Rep 15:15-20
75. Chang YS, di Tomaso E, McDonald DM et al (2000) Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci USA 97:14608-14613 (Pubitemid 32016623)
76. Yao XH, Ping YF, Chen JH et al (2008) Glioblastoma stem cells produce vascular endothelial growth factor by association with a G-protein coupled formylpeptide receptor FPR. J Pathol 215: 369-376
77. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
78. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364 (Pubitemid 26272076)
79. Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396-401 (Pubitemid 39551674)
80. Hendrix MJC, Seftor EA, Gess AR et al (2003) Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Rev Cancer 3:411-421 (Pubitemid 37328845)
81. Zhao Y, Bao Q, Renner A et al (2011) Cancer stem cells and angiogenesis. Int J Dev Biol 55:477-482
82. Venere M, Fine HA, Dirks PB et al (2011) Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer hierarchy. Glia 59:1148-1154
83. Lathia JD, Gallagher J, Heddleston JM et al (2010) Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 6: 421-432
84. Wurmser AE, Nakashima K, Summers RG et al (2004) Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature 430:350-356 (Pubitemid 38937742)
85. Hovinga KE, Shimizu F, Wang R et al (2010) Inhibition of Notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28:1019-1029
86. Jain RK, Duda DG, Willett CG et al (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6:327-338
87. Sorensen AG, Batchelor TT, Zhang WT et al (2009) A ''vascular normalization index'' as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69:5296-5300
88. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172-1183
89. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62 (Pubitemid 40093472)
90. Loges S, Schmidt T, Carmeliet Y (2010) Mechanisms of resistance to anti-angiogenic therapy and development of thirdgeneration anti-angiogenesis drug candidates. Gene Cancer 1: 12-25
91. Saidi A, Hagerdon M, Allain N et al (2009) Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer 125: 1054-1064
92. Chan DA, Kawahara TC, Sutphin PD et al (2009) Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15:527-538
93. Chan DA, Glaccia AJ (2010) PHD2 in tumor angiogenesis. Br J Cancer 103:1-5
94. Henze AT, Riedel J, Diem T et al (2010) Prolyl hydroxylase 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 70:357-366
95. Ohtani K, Dimmeler S (2010) Control of cardiovascular differentiation by microRNAs. Basic Res Cardiol 106:5-11
96. Wurdinger T, Tannous BA, Saydam O et al (2008) miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell 14:382-393
97. Lawler S, Chiocca EA (2009) Emerging functions of microRNAs in glioblastoma. J Neurooncol 92:297-306
98. Fang L, Deng Z, Shatseut T et al (2011) MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrinbeta8. Oncogene 30:806-821
99. Wang Z, Li Y, Kong D et al (2010) Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Lett 292:141-148
100. Liu D, Kruegar J, LeNoble F (2011) The role of blood flow and microRNAs in blood vessel development. Int J Dev Biol 55: 419-429